Hypothesis: Central nervous system delivery of cyclosporine A for therapy of progressive multifocal leukoencephalopathy

Journal of Clinical Virology

Volumn 39, Issue 2, 2007, Pages 156-158

  Focosi, Daniele ^a   Kast, Richard Eric ^b   Maggi, Fabrizio ^c   Vatteroni, Linda ^c   Ceccherini Nelli, Luca ^c   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c Retrovirus Center   (Italy)

Author keywords

Cyclosporine A; JC virus; JCV; NFAT4; PML; Progressive multifocal leukoencephalopathy

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE;

CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEM; HUMAN; IN VIVO CULTURE; LETTER; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

ANIMALS; BRAIN; CAROTID ARTERIES; CYCLOSPORINE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MICE; NFATC TRANSCRIPTION FACTORS; RATS;

EID: 34248683242     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2007.04.004     Document Type: Letter

References (22)

1. Begley D., Squires L., Zlokovic B., Mitrovic D., Hughes C., Revest J., et al. Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A. J Neurochem 55 (1990) 1222-1229
2. Bernareggi A., and Rowland M. Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 19 (1991) 21-50
3. Cefalu W., and Pardridge W. Restrictive transport of a lipid-soluble peptide (cyclosporin) through the blood-brain barrier. J Neurochem 45 (1985) 1954-1956
4. Friberg H., Ferrand-Drake M., Bengtsson F., Halestrap A., and Wieloch T. Cyclosporin, but not FK506, protects mitochondria and neurons against hypoglycemia damage and implicates the mitochondrial permeability transition in cell death. J Neurosci 18 (1998) 5151-5159
5. Gijtenbeek J., van den Bent M., and Vecht C. Cyclosporine neurotoxicity: a review. J Neurol 246 (1999) 339-346
6. Goruppi S., and Kyriakis J.M. The pro-hypertrophic basic helix-loop-helix protein p8 is degraded by the ubiquitin/proteasome system in a protein kinase B/Akt- and glycogen synthase kinase-3-dependent manner, whereas endothelin induction of p8 mRNA and renal mesangial cell hypertrophy require NFAT4. J Biol Chem 279 (2004) 20950-20958
7. Khalili K., and White M. Human demyelinating disease and the polyomavirus JCV. Mult Scler 12 (2006) 133-142
8. Koralnik I.J. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name?. Ann Neurol 60 (2006) 162-173
9. Lemaire M., Pardridge W., and Chaudhuri G. Influence of blood components on the tissue uptake indices of cyclosporin in rats. J Pharmacol Exp Ther 34 (1988) 740-743
10. Lishner M., Perrin R.G., Feld R., Messner H.A., Tuffnell P.G., Elhakim T., et al. Complications associated with Ommaya reservoirs in patients with cancer. The Princess Margaret Hospital experience and a review of the literature. Arch Intern Med 150 (1990) 173-176
11. Manley K., O'hara B., Gee G., Simkevich C., Sedivy J., and Atwood W. NFAT4 is required for JCV infection of glial cells. J Virol 80 24 (2006) 12079-12085
12. Mraz W., Reble B., Kemkes B., and Knedel M. The role of lipoproteins in exchange and transfer of cyclosporin-results from in vitro investigations. Transplant Proc 18 (1986) 1281-1284
13. Mraz W., Zink R.G., Preis A., Illner D., Land W., Diebert W., et al. Distribution and transfer of cyclosporin among the various human lipoprotein classes. Transplant Proc 15 (1983) 2426-2429
14. O'Shaughnessy D., Goldman J.M., Roddie M., and Schofield J.B. Grand Rounds-Hammersmith Hospital: clinicopathological conference dizziness and confusion after bone marrow transplantation. BMJ 309 (1994) 262-265
15. Owen R., Patmore R., Smith G., and Barnard D. Cytomegalovirus-induced T-cell proliferation and the development of progressive multifocal leucoencephalopathy following bone marrow transplantation. Br J Haematol 89 (1995) 196-198
16. Perria L., Rosadini G., and Rossi G. Intracarotid and intravertebral injection of drugs. Prog Brain Res 30 (1968) 231-236
17. Sakata A., Tamai I., Kawazu K., Deguchi Y., Ohnishi T., Saheki A., et al. In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of Cyclosporin A at the blood-brain barrier. Biochem Pharmacol 48 (1994) 1989-1992
18. Shirai A., Naito M., Tatsuta J., Dong J., Hanaoka K., Mikami K., et al. Transport of cyclosporin A across the brain capillary cell monolayer by P-glycoprotein. Biochem Biophys Acta 1222 (1994) 400-404
19. Stoner G., Agostini H., Ryschkewitsch C., Baumhefner R., and Tourtellotte W. Characterization of JC virus DNA amplified from urine of chronic progressive multiple sclerosis patients. Mult Scler 1 (1996) 193-199
20. Tanaka C., Kawai R., and Rowland M. Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues. Drug Metab Dispos 28 (2000) 582-589
21. Trenerry M., and Loring D. Intracarotid amobarbital procedure. The Wada test. Neuroimag Clin N Am 5 (1995) 721-728
22. Yoshimoto T., and Siesjö B. Posttreatment with the immunosuppressant cyclosporin A in transient focal ischemia. Brain Res 839 (1999) 283-291